Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;19(6):904-906.
doi: 10.1513/AnnalsATS.202204-323ED.

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management

Athol U Wells  1
Affiliations
Editorial

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management

Athol U Wells. Ann Am Thorac Soc. 2022 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ghazipura M, Mammen MJ, Bissell BD, Macrea M, Herman DD, Hon SM, et al. Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc . 2022;19:1030–1039. - PubMed
    1. Ghazipura M, Mammen MJ, Herman DD, Hon SM, Bissell BD, Macrea M, et al. Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc . 2022;19:1040–1049. - PubMed
    1. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, IPF Consensus Working Group What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J . 2018;51:1800692. - PubMed
    1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. INBUILD Trial Investigators Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med . 2019;381:1718–1727. - PubMed
    1. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med . 2020;8:147–157. - PubMed

MeSH terms